HOUSTON, March 13,
2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc.
(NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical
company specializing in the development of novel treatments for
primary and metastatic cancers in the brain and central nervous
system, today announced that it is aware that the Federal Deposit
Insurance Corp. has taken control of Silicon Valley Bank ("SVB")
due to liquidity concerns. The Company does not hold any deposits
or investments at SVB.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-it-has-no-exposure-to-silicon-valley-bank-issues-301769684.html
SOURCE CNS Pharmaceuticals, Inc.